Katherine Kelly is a molecular biology major at Princeton University currently writing her senior thesis on personal genome services. As part of her research she would like to interview customers of 23andMe and Navigenics about their experiences of the personal genomics process.
The problem: although she can find plenty of 23andMe customers, she is yet to identify a single customer of Navigenics.
If you are a Navigenics customer that is not financially involved with Navigenics in any way, and would be happy to answer a few
questions (over the phone if possible) about your experience taking
the test, what you expected, and whether it was worth the money, please email Katherine: kwkelly(at)princeton.edu.
(As an aside, I’ve spoken to several people here at the AGBT meeting about the Navigenics customer base – it’s pretty clear that they’re receiving virtually no business directly from customers, although they have apparently had some success convincing companies to enroll their employees under a share-payment scheme. At a panel discussion on Thursday night, Navigenics co-founder David Agus that this approach allows Navigenics to tell companies what proportion of their employees are at genetic risk for obesity, diabetes, and so on. But given the incredibly low predictive power of current genome scans for these conditions (particularly obesity), how useful would this be? And how many people are willing to give their employers access to their genetic information, even in a nominally aggregated and anonymised fashion?)